Wisevoter
U.S.

Bactolife Has Launched Helm Binding Proteins in U.S.

The Danish biotechnology firm is introducing its gut-focused binding protein technology to the American supplement market.

Updated on Sept. 30, 2026 in Healthcare

Isometric editorial illustration of a complex protein structure composed of interconnected geometric spheres in teal and mustard.
Danish biotechnology firm Bactolife has officially launched its Helm Binding Proteins in the United States, targeting the digestive health supplement market. AI Illustration. Upload story photo >

Live Poll

Would you trust new lab-engineered protein supplements for your gut health over traditional probiotics?

Bactolife has officially launched its Helm Binding Proteins in the United States. The technology is featured in the Gutgevity supplement, which is marketed through healthcare practitioner channels to promote gut microbiome stability.

Why it matters

This expansion brings a novel six-mechanism approach to gut health management into the U.S. market. The proteins are specifically engineered to bind and neutralize compounds in the gut to support barrier integrity and digestive balance.

Bactolife recently secured over €30 million, or approximately US$34 million, in a Series B investment round. The Gutgevity supplement utilizes a specific six-mechanism approach to support the gut ecosystem.

The players

Bactolife

This Danish biotechnology company specializes in developing binding protein technology to improve gut health and microbiome stability.

Healthgevity

This organization operates as a partner within the healthcare practitioner channel to distribute clinical-grade wellness supplements.

AceBiome

This firm is a strategic collaborator that previously entered into a joint development agreement with Bactolife in early 2026.

The details

The Helm Binding Proteins function by binding and neutralizing compounds directly within the gut. Healthgevity is handling the distribution of the Gutgevity supplement, which incorporates the Helm IgG Binding Protein LT ingredient.

Timeline

  1. Safety and genotoxicity studies were published in 2025.

  2. Bactolife raised over €30 million in a Series B round in January 2026.

  3. Bactolife collaborated with AceBiome in early 2026.

  4. The U.S. launch was confirmed on September 30, 2026.

  5. The company will showcase its technology from October 28 to 30, 2026.

Market Landscape

The entry of Bactolife into the U.S. market reflects an increasing trend toward precision-engineered ingredients in the digestive health sector. This positioning places the firm alongside established players by utilizing validated safety protocols from the Journal of Applied Toxicology.

Consumers seeking these specific gut-health supplements will primarily encounter them through professional recommendations within the healthcare practitioner channel. This rollout means patients may soon discuss these specialized binding proteins as part of their clinical digestive health plans.

The takeaway

The introduction of binding protein technology represents a shift toward more targeted, mechanism-based approaches for managing gut microbiome health. Practitioners and patients should monitor forthcoming clinical data to better understand how these proteins integrate into long-term digestive care.

What happens next

Bactolife is scheduled to present its binding protein technology at the SupplySide Global trade show in Las Vegas, taking place October 28-30, 2026.

Further reading

For more on the current industry landscape, explore Healthcare.

Live Poll

Would you trust new lab-engineered protein supplements for your gut health over traditional probiotics?